Skip to main content

Table 3 Potential drug-drug and drug-disease interactions

From: Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City

Interactions Patients
n = 624
n (%)
Potential drug-drug interactions 492 (78.8)
Number of potential drug-drug interactions*  
   1 154 (24.7)
   2 92 (14.7)
   3–4 154 (24.7)
   ≥ 5 92 (14.7)
Type D 24 (3.8)
   ACE* inhibitors + potassium-sparing diuretics (or potassium supplementation) 11 (1.8)
   NSAID*+ Methotrexate 5 (0.8)
   NSAID* +anticoagulants (or glucocorticoids) 5 (0.8)
   β blocking agents + Verapamil (or Fluoxetin) 3 (0.4)
Type C 468 (75.0)
   ACE* inhibitors + NSAID* 252 (40.4)
   NSAID*+ low dose ASA* 212 (34.0)
   NSAID*+ sulfonylureas 128 (20.5)
   ACE* inhibitors + low dose ASA* 130 (20.8)
   β blocking agents + NSAID* 107 (17.1)
   NSAID* + Diuretics 105 (16.8)
   ACE* inhibitors + glybenclamide 68 (10.9)
   NSAID*+ other NSAID* 51 (8.2)
   ACE* inhibitors + thiazide diuretics 47 (7.6)
   Pravastatin + bezafibrate 35 (5.6)
   Pentoxiyilline + antihypertensives 37 (5.9)
   Metformin+ ranitidine 40 (6.5)
   Glibenclamide + antimycotics or cotrimoxazole 24 (3.9)
   Furosemide + ACE* inhibitors 21 (3.4)
   ACE* inhibitors + antiacids 19 (3.1)
   Alendronate + NSAIDs* 18 (2.9)
   Insulin + antihypertensive 18 (2.9)
   Pentoxifylline + hypoglycemic agents 14 (2.2)
   Acetaminophen + carbamazepin 14 (2.2)
   Ranitidine + azole type of antimycotics 11 (1.8)
   Others 61 (9.4)
Potential drug-disease interactions 400 (64.1)
Number of potential drug-disease interactions  
   1 346 (55.4)
   ≥ 2 54 (8.7)
NSAIDs* in patients with hypertension and/or chronic heart failure 384 (61.5)
β blocking agents in patients with diabetes mellitus 31 (5.0)
NSAIDs* in patients with chronic renal insufficiency 18 (2.9)
NSAIDs* in patients with previous peptic ulcer 8 (1.3)
Thiazides diuretics in patients with gout 7 (1.1)
Metformin in patients with chronic renal insufficiency or congestive heart failure 6 (1.0)
β blocking agents in patients with peripheral vascular disease 4 (0.6)
β blocking agents in patients with asthma/COPD* 3 (0.5)
Others 5 (1.0)
  1. *ACE: angiotensin-converting enzyme; ASA: acetylsalicylic acid; COPD: chronic obstructive pulmonary disease; NSAID: Non-steroidal anti-inflammatory drugs.